S.2453 would establish onerous and unnecessarily intrusive reporting requirements that stand in stark contrast to the lack of transparency of pricing practices by manufacturers. S.2453, “Ensuring the Value of the…
H.R. 4710 would establish onerous and unnecessarily intrusive reporting requirements that stand in stark contrast to the lack of transparency of pricing practices by manufacturers. H.R. 4710, the “PAUSE” Act…
S.2312 would establish onerous and unnecessarily intrusive reporting requirements that stand in stark contrast to the lack of transparency into the pricing practices by manufacturers S.2312, “HELP” Act, was introduced…
Ryan White Clinics for 340B Access sent a letter to Ken Yeager, a member of the Santa Clara County Board of Supervisors, for his efforts to protect and preserve the…
We write to respond to your February “Open Letter to Grantees” regarding your sponsorship of H.R. 4710, the 340B PAUSE Act. We strongly agree that the 340B program is “one…
The 340B Ceiling Price and Manufacturer Civil Monetary Penalties (CMP) rule may be a delayed a fifth time. On March 27, 2018, HRSA sent to the White House Office of…
The Senate Committee on Health, Education, Labor and Pensions (HELP), which has Senate jurisdiction over the 340B program, will hold a hearing titled “Perspectives on the 340B Drug Discount Program”…
On March 1, 2018, Sen. Chuck Grassley (R-Iowa) introduced legislation that would require new federal government reporting by hospitals regarding their 340B purchases and revenue under the program. The “Ensuring…
On February 9, 2018 the White House Council of Economic Advisors issued a White Paper on “Reforming Biopharmaceutical Pricing at Home and Abroad.” The White Paper identified the 340B program…
President Trump’s 2019 budget request, released on February 12, 2018, included several provisions related to the 340B program. The proposed budget requires all 340B covered entities to report on use…